Michael J. Strong, MD, FRCP(C), FANN, FCAHS

Stong-CIHR---Website_.jpg

Professor of Neurology and President of the Canadian Institutes of Health Research
Office: London Health Sciences Centre, University Hospital C7-120, CSB 3700
Phone: 519-663-3874
Secretary: Sherry Conrad

 

 

Bio Sketch

Dr. Michael J. Strong became the President of the Canadian Institutes of Health Research in October, 2018.  Prior to this, he served as the Dean of the Schulich School of Medicine & Dentistry at Western University where he continues to hold an appointment as a Distinguished University Professor in the Department of Clinical Neurological Sciences, and as a Scientist at the Robarts Research Institute. He was co-chair of the Department of Clinical Neurological Sciences and Chief of Neurology from 2001 – 2010.  He undertook his medical training at Queens University in Kingston (1976 – 1982), neurology training at Western University (1982 – 1987), and postgraduate training at the Laboratory of Central Nervous System Studies (director - D. Carleton Gadjusek, Nobel Laureate) at the National Institutes of Health, Bethesda, Maryland under the supervision of Ralph M. Garruto, PhD (1987 - 1990). 

He has published over 200 peer-reviewed articles and 29 chapters, edited 4 textbooks and given over 170 invited lectures nationally and internationally related to his research in ALS. Dr. Strong was awarded the Sheila Essay Award in 2005 and the Forbes Norris Award in 2008, and is the only Canadian to have received both international awards for ALS research. He was elected as a fellow of the American Academy of Neurology in 2008. In 2009, he was elected a Fellow of the Canadian Academy of Health Sciences.

His research has focused on understanding the cellular biology of ALS (Lou Gehrig’s disease) including the role of altered RNA metabolism in the genesis of neuronal cytoplasmic inclusions and in the clinicopathological correlates of the frontotemporal spectrum disorder that can be associated with ALS. The latter has led to an appreciation for the role of alterations in tau protein metabolism in ALS.


Research

Dr. Strong's research has focused on understanding the cellular biology of ALS (Lou Gehrig’s disease) and has led to an understanding of the mechanisms by which intracellular deposits of protein (composed primarily of neurofilament) are formed, and how these aggregates contribute to the disease process of ALS.  His research has also contributed to the understanding of neuropsychological deficits in ALS, both clinically and at the cellular level.


Medical Interests

Lou Gehrig's Disease (ALS: degeneration of motor neurons), Motor Neuron Diseases, Neurotoxicity


Honours and Awards

  • 2012, Queen Elizabeth II Diamond Jubilee Medal
  • 2012, Excellence in teaching Award, Western University Students' Council
  • 2012, Teaching Honour Roll Certificate, Western University
  • 2009, Distinguished University Professorhsip Award, Western University
  • 2008, Excellence in Teaching Award, Western University
  • 2007, Excellence in Teaching Award, Western University
  • 2006, Faculty scholar, Schulich School of Medicine & Dentistry
  • 2006, Excellence in Teaching Award, Western University
  • 2005, Excellence in Teaching Award, Western University
  • 2004, Excellence in Teaching Award, Western University

 

Publications

PubMed Publications Listing

Publications

Hawley ZCE, Campos-Melo D, Strong MJ. Novel miR-b2122 regulates several ALS-related RNA-binding proteins. Mol Brain. 2017 Oct 2;10(1):46. doi: 10.1186/s13041-017-0326-7. PubMed PMID: 28969660.

Farhan SMK, Gendron TF, Petrucelli L, Hegele RA, Strong MJ. ARHGEF28 p.Lys280Metfs40Ter in an amyotrophic lateral sclerosis family with a C9orf72 expansion. Neurol Genet. 2017 Sep 22;3(5):e190. doi: 10.1212/NXG.0000000000000190. eCollection 2017 Oct. PubMed PMID: 28971145; PubMed Central PMCID: PMC5616022.

Strong MJ. Revisiting the concept of amyotrophic lateral sclerosis as a multisystems disorder of limited phenotypic expression. Curr Opin Neurol. 2017 Sep 13. doi: 10.1097/WCO.0000000000000488. [Epub ahead of print] PubMed PMID: 28914734.

Strong MJ, Busing N, Goosney DL, Harris KA, Horsley T, Kuzyk A, Lingard L, Norman WV, Rosenblum ND, Saryeddine T, Wang X. The Rising Challenge of Training Physician-Scientists: Recommendations From a Canadian National Consensus Conference. Acad Med. 2017 Aug 16. doi: 10.1097/ACM.0000000000001857. [Epub ahead of print] PubMed PMID: 28817429.

Cheung K, Droppelmann CA, MacLellan A, Cameron I, Withers B, Campos-Melo D, Volkening K, Strong MJRho guanine nucleotide exchange factor (RGNEF) is a prosurvival factor under stress conditions. Mol Cell Neurosci. 2017 Jul;82:88-95. doi: 10.1016/j.mcn.2017.05.003. Epub 2017 May 8. PMID: 28495450

Montero-Odasso M, Pieruccini-Faria F, Bartha R, Black SE,Finger E, Freedman M, Greenberg B, Grimes DA, Hegele RA, Hudson C, Kleinstiver PW, Lang AE, Masellis M, McLaughlin PM, Munoz DP, Strother S, Swartz RH, Symons S, Tartaglia MC, Zinman L,Strong MJMotor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). ONDRI Investigators., McIlroy W.J Alzheimers Dis. 2017 Jun 27. doi: 10.3233/JAD-170149. [Epub ahead of print] PubMed PMID: 28671116.

Volkening K, Strong WL, Seaton S, Yang W, Strong MJC9orf72 mutations do not influence the tau signature of amyotrophic lateral sclerosis with cognitive impairment (ALSci). Amyotroph Lateral Scler Frontotemporal Degener. 2017 May 31:1-6. doi: 10.1080/21678421.2017.1332075. [Epub ahead of print] PMID: 28562075

Hawley ZCE, Campos-Melo D, Droppelmann CA, Strong MJMotomiRs: miRNAs in Motor Neuron Function and Disease.Front Mol Neurosci. 2017 May 4;10:127. doi: 10.3389/fnmol.2017.00127. eCollection 2017. Review. PMID: 28522960

Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, Mioshi E, Roberts-South A, Benatar M, HortobáGyi T, Rosenfeld J, Silani V, Ince PG, Turner MR. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):153-174. doi: 10.1080/21678421.2016.1267768. Epub 2017 Jan 5. PMID: 28054827

Farhan SM, Bartha R, Black SE, Corbett D, Finger E, Freedman M, Greenberg B, Grimes DA, Hegele RA, Hudson C, Kleinstiver PW, Lang AE, Masellis M, McIlroy WE, McLaughlin PM, Montero-Odasso M, Munoz DG, Munoz DP, Strother S, Swartz RH, Symons S, Tartaglia MC, Zinman L; ONDRI Investigators, Strong MJ. The Ontario Neurodegenerative Disease Research Initiative (ONDRI). Can J Neurol Sci. 2017 Mar;44(2):196-202. doi: 10.1017/cjn.2016.415. Epub 2016 Dec 22. PMID:28003035

Moszczynski AJ, Yang W, Hammond R, Ang LC, Strong MJThreonine175, a novel pathological phosphorylation site on tau protein linked to multiple tauopathies. Acta Neuropathol Commun. 2017 Jan 11;5(1):6. doi: 10.1186/s40478-016-0406-4. PMID: 28077166

News

Social Media Coverage